Table 4.
Evaluation of microRNA performance in predicting 1 year risk of mortality.
| microRNA | N | SHR (95% CI) |
|---|---|---|
| (A) | ||
| miR-103a | 154 | 1.00 (0.82–1.21) |
| miR-122 | 154 | 1.01 (0.98–1.03) |
| miR-150 | 154 | 1.04 (1.00–1.08) |
| miR-16-2 | 153 | 1.02 (0.98–1.07) |
| miR-17 | 129 | 1.01 (0.97–1.05) |
| D/ND miR-17 | 154 | 0.56 (0.24–1.30) |
| miR-191 | 151 | 1.52 (1.12–2.05) |
| D/ND miR-200b | 154 | 1.21 (0.40–3.64) |
| miR-20a | 116 | 1.03 (0.95–1.12) |
| D/ND miR-20a | 154 | 1.58 (0.61–4.13) |
| miR-223 | 154 | 1.24 (0.999–1.54) |
| miR-23a | 154 | 1.20 (1.04–1.40) |
| miR-24 | 154 | 1.20 (1.08–1.35) |
| miR-25 | 154 | 1.04 (0.99–1.10) |
| miR-26a | 154 | 0.79 (0.63–0.99) |
| miR-27a | 154 | 1.08 (0.88–1.33) |
| miR-29b | 154 | 1.03 (0.98–1.08) |
| miR-30a | 154 | 1.02 (0.99–1.06) |
| miR-330 | 54 | 1.08 (0.995–1.17) |
| D/ND miR-330 | 154 | 0.48 (0.19–1.19) |
| miR-451 | 154 | 1.04 (0.98–1.11) |
| miR-503 | 117 | 0.99 (0.94–1.04) |
| D/ND miR-503 | 154 | 0.99 (0.43–2.27) |
| D/ND miR-663 | 154 | 0.53 (0.06–4.10) |
| microRNA | MELD aSHR (95% CI) | |
|---|---|---|
| (B) | ||
| miR-150 | 1.03 (0.98–1.08) | |
| miR-191 | 1.85 (1.32–2.60) | |
| miR-23a | 1.08 (0.87–1.33) | |
| miR-24 | 1.10 (0.93–1.30) | |
| miR-26a | 0.84 (0.66–1.07) | |
| microRNA | CP aHR (95% CI) | |
|---|---|---|
| (C) | ||
| miR-150 | 1.02 (0.98–1.07) | |
| miR-191 | 1.63 (1.19–2.24) | |
| miR-23a | 1.08 (0.92–1.28) | |
| miR-24 | 1.06 (0.92–1.21) | |
| miR-26a | 0.83 (0.66–1.05) | |
| microRNA | MELD aSHR (95% CI) | |
|---|---|---|
| (D) | ||
| miR-191 (ARLD) | 1.88 (1.30–2.72) | |
| miR-191 (Ascites) | 1.91 (1.37–2.65) | |
| miR-16-2 (dCLD) | 1.08 (1.01–1.15) | |
| miR-24 (dCLD) | 1.40 (1.04–1.90) | |
| microRNA | CP aSHR (95% CI) | |
|---|---|---|
| (E) | ||
| miR-191 (ARLD) | 1.66 (1.13–2.43) | |
| miR-191 (Ascites) | 1.59 (1.16–2.19) | |
| miR-24 (dCLD) | 1.36 (1.01–1.82) | |
(A) Competing risk analysis for 1 year risk of mortality. (B) MELD adjustment of prevalently expressed microRNA which discriminated 1 year risk of mortality. Performance of MELD adjusted miR-191; n = 148, Wald Chi2 = 26.31, p < 0.001*. (C) CP adjustment of prevalently expressed microRNA which discriminated 1 year risk of mortality. Performance of CP adjusted miR-191; n = 148, Wald Chi2 = 53.69, p < 0.001*. (D) microRNA which discriminated outcome on sensitivity analyses and remained significant following adjustment for MELD. (E) microRNA which discriminated outcome on sensitivity analyses and remained significant following adjustment for CP. D/ND = microRNA converted into categorical variable and marked as detected = 1 or not detected = 0. See Supplementary Tables 8–10 for model performance.